Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19636434 | 1.00 | PDE4D (0.32) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19632930 | 0.89 | PDE4D (0.32) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19636435 | 0.89 | PDE4D (0.32) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19229339 | 0.89 | PDE4D (0.35) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19229289 | 0.89 | PDE4D (0.35) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19632818 | 0.86 | PDE4D (0.32) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19636515 | 0.86 | PDE4D (0.32) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19632941 | 0.84 | SLC29A1 (0.31) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19636530 | 0.84 | SLC29A1 (0.31) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL19636529 | 0.78 | ADORA2A (0.32) | PDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334941-A1 | 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | EMORY UNIVERSITY | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334941-A1 | 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | HAVCR2, DERA, EIF2AK2 | PDE4D 2437/4885PDE3A 3345/4885SLC29A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.